Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

By afschroeder • February 17, 2026

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai TY, Revaiah PC, Dunne F, Mehran R, Budoff MJ, Kastelein JJ, Stroes ESG, Khamis R, Koenig W, Onuma Y. Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention. 2026 Feb 16;22(4):202-223. doi: 10.4244/EIJ-D-25-00598. PMID: 41697657.

Tags: Cardiology/Epi, Harbor UCLA, Publications

Related Posts

Air Pollution Triggers Metabolomic Signature of Mitochondrial Dysfunction in Mice and Humans: Implications for Cardiovascular Disease Development

Lin Y, Qiu X, Gupta R, Ramanathan G, Lu X, Yin F, Fiehn O, Zhang JJ, Kaufman JD, Zhu Y, Rosenfeld M, Araujo JA. Air[...]

Lamin B1 Coordinates the Assembly of the Nuclear Lamina

Kim JR, Kim PH, Tu Y, Carroll J, Koerner JP, Young SG, Fong LG. Lamin B1 Coordinates the Assembly of the Nuclear Lamina. J Cell[...]

Regulators of Mineralization and Long-Term Progression of Aortic Valve and Mitral Annular Calcification: MESA

Bortnick AE, Naveed M, Fu X, Shea K, Kestenbaum B, de Boer I, Ix JH, Kim R, Hamerton E, Kankaria R, Tracy RP, Tsai M,[...]